Use and feasibility of a Lynch Syndrome predictive model for inherited colorectal and endometrial cancer in a low-middle income country

While universal tumor testing for Lynch Syndrome (LS) is recommended in all new diagnoses of colorectal cancer (CC) and endometrial cancer (EC), the cost and availability of this test in low-resource settings poses challenges. The PREdiction Model for gene Mutations (PREMM₅) is a clinical algorithm designed to assess the risk of an individual carrying estimates one’s risk of carrying a LS mutation. This study aims to assess the feasibility of using PREMM₅ to screen for LS risk in Guatemala. This cross-sectional pilot study enrolled 50 patients with colorectal or endometrial cancer receiving treatment at LIGA-INCAN, a cancer hospital in Guatemala City, between June 2022–July 2022. Patients were contacted by phone and administered the PREMM₅ survey, followed by an additional feasibility questionnaire. Of the 50 participants, 62% of patients had a PREMM₅ predicted probability of ≥ 2.5%, the threshold above which genetic testing is recommended. Almost all patients found the survey easy to complete (98%), were able to easily recall personal (90%) and family (88%) medical history, understood its purpose (94%), and reported an interest in (96%) and ability to (98%) act on the results if applicable. Our study shows the role of the PREMM₅ as a feasible tool for identifying individuals at risk of carrying mutations associated with LS in this low-resource setting. By implementing the PREMM₅ model, high risk individuals can be identified early, enabling timely interventions and improving outcomes in this at-risk population.